News Cybin Inc.

Equities

CYBN

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:10:00 2025-06-18 pm EDT			5-day change	1st Jan Change
7.900 ^USD	+2.46%		-8.67%	-10.43%

Jun. 13	Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics	CI
Jun. 13	Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics	RE

Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics	Jun. 13	CI
Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics	Jun. 13	RE
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics	Jun. 13	BU
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference	Jun. 12	BU
Cybin to Participate in the 2025 Psychedelic Science Conference	Jun. 11	BU
Cybin Granted Additional US Patent for Potential Anxiety Disorder Treatments	Jun. 03	MT
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder	Jun. 03	BU
Cybin Inc. - Special Call	May. 29
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025	May. 22	BU
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics	May. 20	BU
Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program	May. 15	MT
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder	May. 15	BU
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase	May. 14	BU
Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder	May. 08	CI
Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder	May. 08	RE
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder	May. 08	BU
Cybin to Participate at the 28th Annual Milken Institute Global Conference	May. 01	BU
Cybin Says Second Phase 3 Study Embrace Expected To Begin Mid-2025	Apr. 23	RE
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003	Apr. 23	BU
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003	Apr. 23	CI
Cybin Partners With Osmind to Support Psychiatry Program Pipeline	Apr. 21	MT
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs	Apr. 21	BU
Cybin Inc. Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs	Apr. 21	CI
Cybin : Corporate Presentation February 2025	Feb. 11	PU
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights	Feb. 10	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cybin Inc.

Equities

CYBN

CA23256X4075

Biotechnology & Medical Research

Filters